The efficacy and safety of adapalene gel 0.3% in the treatment of acne vulgaris: A randomized, multicenter, investigator-blinded, controlled comparison study versus adapalene gel 0.1% and vehicle

Cutis

Volumn 76, Issue 2, 2005, Pages 145-151

  Pariser, David M ^a   Thiboutot, Diane M ^b   Clark, Scott D ^c   Jones, Terry M ^d   Liu, Yin ^e   Graeber, Michael ^e,f  

^a EASTERN VIRGINIA MEDICAL SCHOOL   (United States)

^b PENN STATE MILTON S HERSHEY MEDICAL CENTER   (United States)

^c Longmont Clinic   (United States)

^d J and S Studies Inc   (United States)

^e Galderma R and D Inc   (United States)

^f Galderma R and D Inc   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ADAPALENE; DERMATOLOGICAL AGENT; DRUG VEHICLE; NAPHTHALENE DERIVATIVE;

ACNE VULGARIS; ADOLESCENT; ADULT; ARTICLE; CHILD; CLINICAL TRIAL; COMPARATIVE STUDY; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; FEMALE; GEL; HUMAN; MALE; MULTICENTER STUDY; RANDOMIZED CONTROLLED TRIAL; SINGLE BLIND PROCEDURE; TOPICAL DRUG ADMINISTRATION; VEHICLES;

ACNE VULGARIS; ADMINISTRATION, TOPICAL; ADOLESCENT; ADULT; CHILD; DERMATOLOGIC AGENTS; FEMALE; GELS; HUMANS; MALE; NAPHTHALENES; SINGLE-BLIND METHOD; VEHICLES;

EID: 24744452193     PISSN: 00114162     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (20)

1. Gollnick H, Schramm M. Topical drug treatment in acne. Dermatology. 1998;196:119-125.
2. Brogden RN, Goa KL. Adapalene: a review of its pharmacological properties and clinical potential in the management of mild to moderate acne. Drugs. 1997;53:511-519.
3. Michel S, Jomard A, Demarchez M. Pharmacology of adapalene. Br J Dermatol. 1998;139(suppl 52):3-7.
4. Vega B, Jomard A, Michel S. Regulation of human monocyte toll-like receptor 2 (TLR2) expression by adapalene [abstract]. J Eur Acad Dermatol Venereol. 2002;16(suppl 1):123-124.
5. Cunliffe WJ, Caputo R, Dreno B, et al. Clinical efficacy and safety comparison of adapalene gel and tretinoin gel in the treatment of acne vulgaris: Europe and US multicenter trials. J Am Acad Dermatol. 1997;36:S126-S134.
6. Shalita A, Weiss JS, Chalker DK, et al. A comparison of the efficacy and safety of adapalene gel 0.1% and tretinoin gel 0.025% in the treatment of acne vulgaris: a multicenter trial. J Am Acad Dermatol. 1996;34:482-485.
7. Grosshans E, Marks R, Mascaro JM, et al. Evaluation of clinical efficacy and safety of adapalene 0.1% gel versus tretinoin 0.025% gel in the treatment of acne vulgaris, with particular reference to the onset of action and impact on quality of life. Br J Dermatol. 1998;139:26-33.
8. Thiboutot D, Gold MH, Jarratt MT, et al. Randomized controlled trial of the tolerability, safety, and efficacy of adapalene gel 0.1% and tretinoin microsphere gel 0.1% for the treatment of acne vulgaris. Cutis. 2001;68(suppl 4):10-19.
9. Cunliffe WJ, Poncet M, Loesche C, et al. A comparison of the efficacy and tolerahility of adapalene 0.1% gel versus tretinoin 0.025% gel in patients with acne vulgaris: a meta-analysis of five randomized trials. Br J Dermatol. 1998;139:48-56.
10. Wolf JE Jr, Kaplan D, Kraus SJ, et al. Efficacy and tolerahility of combined topical treatment of acne vulgaris with adapalene and clindamycin: a multicenter, randomized, investigator-blinded study. J Am Acad Dermatol. 2003;49:S211-S217.
11. Cunliffe WJ, Meynadier J, Alirezai M, et al. Is combined oral and topical therapy better than oral therapy alone in patients with moderate to moderately severe acne vulgaris? a comparison of the efficacy and safety of lymecycline plus adapalene gel 0.1%, versus lymecycline plus gel vehicle. J Am Acad Dermatol. 2003;49(suppl 3):S218-S226.
12. Gollnick H, Cunliffe W, Berson D, et al. Management of acne: a report from a Global Alliance to Improve Outcomes in Acne. J Am Acad Dermatol. 2003;49(suppl 1):S1-S37.
13. Dosik JS, Homer K, Arsonnaud S. Cumulative irritation potential of adapalene 0.1% cream and gel compared with tazarotene cream 0.05% and 0.1%. Cutis. 2005;75:289-293.
14. Greenspan A, Loesche C, Vendetti N, et al. Cumulative irritation comparison of adapalene gel and solution with 2 tazarotene gels and 3 tretinoin formulations. Cutis. 2003;72:76-81.
15. Brand B, Gilbert R, Baker MD, et al. Cumulative irritancy comparison of adapalene gel 0.1% versus other retinoid products when applied in combination with topical antimicrobial agents. J Am Acad Dermatol. 2003;49(suppl 3):S227-S232.
16. Dunlap FE, Mills OH, Tuley MR, et al. Adapalene 0.1% gel for the treatment of acne vulgaris: its superiority compared to tretinoin 0.025% cream in skin tolerance and patient preference. Br J Dermatol. 1998;139:17-22.
17. Caron D, Sorba V, Kerrouche N, et al. Split-face comparison of adapalene 0.1% gel and tretinoin 0.025% gel in acne patients. J Am Acad Dermatol. 1997;36(suppl 6, pt 2):S110-S112.
18. Egan N, Loesche MC, Baker MM. Randomized, controlled, bilateral (split-face) comparison trial of the tolerability and patient preference of adapalene gel 0.1% and tretinoin microsphere gel 0.1% for the treatment of acne vulgaris. Cutis. 2001;68(suppl 4):20-24.
19. O'Brien SC, Lewis JB, Cunliffe WJ. The Leeds Revised Acne Grading System. J Dermatol Treat. 1998;9:215-220.
20. Thiboutot DM, Pariser DM, Egan N, et al. Adapalene gel 0.3% for the treatment of acne vulgaris: a randomized, controlled trial. J Am Acad Dermatol. In press.